189 related articles for article (PubMed ID: 4038404)
1. Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia.
Yang JL; Cheng EH; Capizzi RL; Cheng YC; Kute T
J Clin Invest; 1985 Jan; 75(1):141-6. PubMed ID: 4038404
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
4. High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides.
Sinkule JA; Evans WE
J Chromatogr; 1983 May; 274():87-93. PubMed ID: 6575975
[TBL] [Abstract][Full Text] [Related]
5. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
[TBL] [Abstract][Full Text] [Related]
6. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.
Capizzi RL; Yang JL; Cheng E; Bjornsson T; Sahasrabudhe D; Tan RS; Cheng YC
J Clin Oncol; 1983 Dec; 1(12):763-71. PubMed ID: 6668493
[TBL] [Abstract][Full Text] [Related]
7. Sensitive radioimmunoassay for cytarabine and uracil arabinoside in plasma.
Sato T; Morozumi M; Kodama K; Kuninaka A; Yoshino H
Cancer Treat Rep; 1984 Nov; 68(11):1357-66. PubMed ID: 6498853
[TBL] [Abstract][Full Text] [Related]
8. Does the metabolite uracil arabinoside inhibit cytosine arabinoside (Ara-C) penetration into the cerebrospinal fluid during high-dose Ara-C therapy?
van Prooijen HC; Muus P; Roelofs JM; Punt K
Scand J Haematol; 1986 Jan; 36(1):123-6. PubMed ID: 3456631
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
Schwartz SA; Morgenstern B; Capizzi RL
Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
[TBL] [Abstract][Full Text] [Related]
10. Liquid-chromatographic monitoring of cytosine arabinoside and its metabolite, uracil arabinoside, in serum.
Wermeling JR; Pruemer JM; Hassan FM; Warner A; Pesce AJ
Clin Chem; 1989 Jun; 35(6):1011-5. PubMed ID: 2731341
[TBL] [Abstract][Full Text] [Related]
11. Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia.
Yang JL; White JC; Capizzi RL
Cancer Chemother Pharmacol; 1990; 26(2):135-8. PubMed ID: 2347039
[TBL] [Abstract][Full Text] [Related]
12. Micellar electrokinetic capillary chromatography quantification of cytosine arabinoside and its metabolite, uracil arabinoside, in human serum.
Houzé P; Deschamps F; Dombret H; Bousquet B; Gourmel B
J Chromatogr B Biomed Sci Appl; 2001 Apr; 754(1):185-92. PubMed ID: 11318414
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous determination of cytosine arabinoside and its metabolite, uracil arabinoside, in human plasma using hydrophilic interaction liquid chromatography with UV detection.
Uchiyama M; Takamatsu Y; Ogata K; Matsumoto T; Jimi S; Tamura K; Hara S
Biomed Chromatogr; 2013 Jul; 27(7):818-20. PubMed ID: 23420764
[TBL] [Abstract][Full Text] [Related]
14. High-performance liquid chromatographic assay for cytosine arabinoside and uracil arabinoside in cerebrospinal fluid and plasma.
Riccardi A; Servidei T; Lasorella A; Riccardi R
J Chromatogr; 1989 Dec; 497():302-7. PubMed ID: 2625467
[No Abstract] [Full Text] [Related]
15. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
16. Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation.
Capizzi RL; Yang JL; Rathmell JP; White JC; Cheng E; Cheng YC; Kute T
Semin Oncol; 1985 Jun; 12(2 Suppl 3):65-74. PubMed ID: 3892704
[No Abstract] [Full Text] [Related]
17. Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.
Kreis W; Woodcock TM; Gordon CS; Krakoff IH
Cancer Treat Rep; 1977 Oct; 61(7):1347-53. PubMed ID: 589600
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients.
Donnette M; Solas C; Giocanti M; Venton G; Farnault L; Berda-Haddad Y; Hau LTT; Costello R; Ouafik L; Lacarelle B; Ciccolini J; Fanciullino R
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1126-1127():121770. PubMed ID: 31454720
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic liponucleotide analogs. II. Antitumor activity of CDP-diacylglycerol analogs containing the cytosine arabinoside moiety.
Turcotte JG; Srivastava SP; Steim JM; Calabresi P; Tibbetts LM; Chu MY
Biochim Biophys Acta; 1980 Sep; 619(3):619-31. PubMed ID: 7459369
[TBL] [Abstract][Full Text] [Related]
20. Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure.
Radeski D; Cull GM; Cain M; Hackett LP; Ilett KF
Cancer Chemother Pharmacol; 2011 Apr; 67(4):765-8. PubMed ID: 20532508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
